Menu Content/Inhalt
Search  

PRESS RELEASES


   Order     Display # 
Date Item Title
29-Jul-2003 Debiopharm S.A. and Dyax Corp. granted European Orphan Drug Status for EPI-hNE4 (DX-890) for Cystic Fibrosis Indication
04-Jun-2003 DEBIOPHARM S.A. licenses-in a compound from Genodyssee S.A.
23-Mar-2003 Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004
17-Mar-2003 H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing in Oncology
16-Jan-2003 Debiopharm S.A. provides funding to Tulane University
19-Nov-2002 Debiopharm S.A. announces a patent application on a hydrosoluble prodrug of cyclosporin A
24-Oct-2002 Debiopharm S.A. licenses-in new technology to turn injectable macromolecular drugs into oral formulations
12-Sep-2002 Debiopharm and Biolex sign collaboration
15-Jul-2002 Dyax Corp. and Debiopharm S.A. report successful results of phase IIA clinical trial with DX-890 for cystic fibrosis
27-Jun-2002 Debiopharm S.A. inaugurates a new State-of-the-Art Galenic Unit in Gland, Switzerland
14-May-2002 Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury
12-Mar-2002 Swiss company Debio R.P. announces Agreement with Inhale subsidiary Shearwater Corporation
07-Jun-2001 New pharmaceutical development company in Quebec : The SGF and the Swiss Group Debio create H3 BioDé
13-Feb-2001 Dyax Corp. and Debiopharm S.A. report initiation of phase II clinical trial with EPI-HNE-4 for cystic fibrosis
 
< Prev 1 2 3 Next >
Results 41 - 54 of 54